Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Jeffrey W. Scott"'
Autor:
Luojun Victor Wang, Yvonne Y. Lau, Thomas John, Giovanni Selvaggi, Filippo de Braud, Jeffrey W. Scott, Enriqueta Felip, Vanessa Giannone, O. Alejandro Balbin, Michela Maur, Daniel Shao-Weng Tan, Pilar Cazorla, Martijn P. Lolkema, Herbert H. Loong, Johan Vansteenkiste, Alice T. Shaw, Jason Baum, Geoffrey Liu
Publikováno v:
Journal of Thoracic Oncology, 15(3), 392-403. International Association for the Study of Lung Cancer
Scientia
Scientia
INTRODUCTION: Induction of programmed death ligand 1 (PD-L1) expression due to constitutive oncogenic signaling has been reported in NSCLC models harboring echinoderm microtubule associated protein like 4 gene (EML4)-ALK receptor tyrosine kinase gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c585261ab269021e80247d15a18cb62
https://doi.org/10.1016/j.jtho.2019.10.006
https://doi.org/10.1016/j.jtho.2019.10.006
Autor:
Felipe K. Hurtado, Javier de Castro Carpeño, Yvonne Y. Lau, Tracey McCulloch, Morten Mau-Sørensen, Maria Jose de Miguel Luken, Jeffrey W. Scott, Filippo de Braud, Ding Wang
Publikováno v:
Hurtado, F K, de Braud, F, De Castro Carpeño, J, de Miguel Luken, M J, Wang, D, Scott, J, Lau, Y Y, McCulloch, T & Mau-Sorensen, M 2021, ' Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates : a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors ', Cancer Chemotherapy and Pharmacology, vol. 87, no. 4, pp. 475-486 . https://doi.org/10.1007/s00280-020-04180-3
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology
Purpose Ceritinib is an ALK receptor tyrosine kinase inhibitor approved as first- and second-line treatment in adult patients with ALK + metastatic non-small cell lung cancer (NSCLC). The study investigated the drug–drug interaction (DDI) potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81b7629bcf32733253af4fe4d44e0a1c
https://curis.ku.dk/portal/da/publications/effect-of-ceritinib-on-the-pharmacokinetics-of-coadministered-cyp3a-and-2c9-substrates(8b1ee85c-4824-47f5-a541-f7f001f03315).html
https://curis.ku.dk/portal/da/publications/effect-of-ceritinib-on-the-pharmacokinetics-of-coadministered-cyp3a-and-2c9-substrates(8b1ee85c-4824-47f5-a541-f7f001f03315).html
Autor:
Marwan Ghosn, Anna Wrona, Gloria Borra, Keunchil Park, Yvonne Y. Lau, Richard Yu, Alastair Greystoke, Karen Osborne, Sang We Kim, Vanessa Q. Passos, Evaristo Maiello, Byoung Chul Cho, Wen Gu, Jeffrey W. Scott, Dong Wan Kim, Alessandra Bearz, Scott A. Laurie, Mark J. McKeage, Andrea Ardizzoni
Publikováno v:
Journal of Thoracic Oncology. 12:1357-1367
Introduction Ceritinib, 750 mg fasted, is approved for treatment of patients with ALK receptor tyrosine kinase gene (ALK)-rearranged (ALK-positive) NSCLC previously treated with crizotinib. Part 1 of the ASCEND-8 study determined whether administerin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cb292fca972eaa143dcd634099e2ba3
https://doi.org/10.1016/j.jtho.2017.07.005
https://doi.org/10.1016/j.jtho.2017.07.005
Autor:
Jordi Esteve, Pierre Fenaux, Jeffrey W. Scott, Hee-Je Kim, Severine Peyrard, Yasushi Miyazaki, Uwe Platzbecker, Fei Ma, Julie Niolat, Valeria Santini, Mario Stegert, Zhijian Xiao, Andre C. Schuh, Kamel Malek, Sabine Hertle, Amer M. Zeidan, Flavia Kiertsman, Jörg Westermann, Aristoteles Giagounidis, Mikkael A. Sekeres
Publikováno v:
Blood. 136:45-46
Background: Therapy options for pts with HR-MDS or AML who are not candidates for intensive chemotherapy (IC) or hematopoietic stem cell transplantation (HSCT) are limited, and clinical outcomes are poor. Novel, effective and tolerable therapies are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3098f78d7ab365c505f72200fc6fa06f
https://doi.org/10.1182/blood-2020-134718
https://doi.org/10.1182/blood-2020-134718
Publikováno v:
The Journal of Clinical Pharmacology. 56:559-566
Ceritinib is a potent inhibitor of anaplastic lymphoma kinase (ALK), which has shown acceptable safety and substantial antitumor activity in ALK-positive non-small cell lung cancer (NSCLC) patients. Two food-effect studies were conducted in healthy a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3938ed1b154dfc069e11177d95a314fc
https://doi.org/10.1002/jcph.619
https://doi.org/10.1002/jcph.619
Autor:
Meral Beksac, Andrew Spencer, Ghulam Kalimi, Michael M Shi, Natalie S. Callander, Christof Scheid, Donna E. Reece, A. Keith Stewart, Can Cai, Pieter Sonneveld, Jeffrey W. Scott
Publikováno v:
European Journal of Haematology, 95(4), 316-324. Wiley-Blackwell Publishing Ltd
Objectives Approximately 15% of patients with multiple myeloma (MM) exhibit a t(4;14) translocation, which often results in constitutive activation of the receptor tyrosine kinase (RTK) fibroblast growth factor receptor 3 (FGFR3). This study evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f287b7d4ff5fc35feabc458a30f91e5b
https://hdl.handle.net/1765/87177
https://hdl.handle.net/1765/87177
Autor:
Kalyanee Viraswami-Appanna, Jeffrey W. Scott, Wen Gu, Yvonne Y. Lau, Tiffany Lin, Michael Shi, Can Cai
Publikováno v:
Cancer chemotherapy and pharmacology. 79(6)
The impact of proton pump inhibitors (PPIs) on the pharmacokinetics (PK) and efficacy of ceritinib was evaluated. A healthy subject drug–drug interaction (DDI) study was conducted to assess the effect of esomeprazole on the PK of a single 750 mg do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bec221905d0f4a5b48386a447bd3563
https://pubmed.ncbi.nlm.nih.gov/28424965
https://pubmed.ncbi.nlm.nih.gov/28424965
Autor:
Daniel J. George, Carolyn D. Britten, Sunil Sharma, Joanne E. Mortimer, Swarupa Kulkarni, Angela Liu, Michelle Quinlan, Jeffrey W. Scott
Publikováno v:
Cancer Chemotherapy and Pharmacology. 74:867-874
This 2-arm, phase 1, crossover study compared the relative bioavailability of two dovitinib (TKI258) capsule formulations [anhydrate clinical service form (CSF) and monohydrate final market image (FMI); Arm 1] and determined the effect of food on dov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::493e4cd13f2f70f9700216826e7ed654
https://doi.org/10.1007/s00280-014-2454-4
https://doi.org/10.1007/s00280-014-2454-4
Autor:
Jeffrey W. Scott, Manish R. Patel, Carlos Becerra, Justine Yang Bruce, Eugene Tan, A. Craig Lockhart, Sanjay Goel, John Sarantopoulos, Shu Yang, Shubham Pant, Vincent Chung, Fairooz F. Kabbinavar, Pamela N. Munster, Hussein Abdul-Hassan Tawbi, Gary Carlson, Sunil Sharma, Jeffrey R. Infante
Publikováno v:
Cancer chemotherapy and pharmacology. 78(5)
A capsule formulation of the tyrosine kinase inhibitor dovitinib (TKI258) was recently studied in a phase 3 renal cell carcinoma trial; however, tablets are the planned commercial formulation. Therefore, this randomized 2-way crossover study evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c38b78787d2fa88044c9dbaa0cdcf68
https://pubmed.ncbi.nlm.nih.gov/27681579
https://pubmed.ncbi.nlm.nih.gov/27681579
Autor:
Kerstin Schwarz, Annette Romanski, Anja Vogel, Elena Puccetti, Jeffrey W. Scott, Gesine Bug, Sarah Wietbrauk, Hubert Serve, Maren Keller
Publikováno v:
Leukemia Research. 35:119-125
AML progenitor cells (AML-PC) undergo significant apoptosis in response to the deacetylase inhibitor (DACi) LAQ824 and lose the replating capacity which was not observed with the DACi valproic acid. Treatment of normal hematopoietic progenitor cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::045962f68ab6e44055075a8a88be0487
https://doi.org/10.1016/j.leukres.2010.06.024
https://doi.org/10.1016/j.leukres.2010.06.024